Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
07 août 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results
14 mai 2019 16h05 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results
08 mai 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
27 mars 2019 16h05 HE
|
Cyclacel
– Conference Call Scheduled March 27, 2019 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J., March 27, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or...
Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor
25 mars 2019 07h00 HE
|
Cyclacel
-- PALOMA-3 study gene expression profiling shows that CDK2 is a key kinase bypass mechanism after treatment with palbociclib plus hormone therapy -- -- Cyclin E is proposed as the first predictive...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results
20 mars 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
13 mars 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019
05 mars 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
07 janv. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco
27 déc. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 27, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...